<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161276</url>
  </required_header>
  <id_info>
    <org_study_id>TNTL-14-01</org_study_id>
    <nct_id>NCT02161276</nct_id>
  </id_info>
  <brief_title>Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule</brief_title>
  <acronym>TNTL</acronym>
  <official_title>Phase 2 Study of The Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guizhou Bailing Group Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guizhou Bailing Group Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of diabetes mellitus with Traditional Chinese Medicine has a long history.&#xD;
&#xD;
      aim： --establish the optimal dosage of traditional Chinese medicine Tang Ning Tongluo Capsule&#xD;
      to treat type II diabetes mellitus.&#xD;
&#xD;
      ---Preliminary evaluate the clinical efficacy and safety of Tangning Tongluo Capsule in the&#xD;
      treatment of type II diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary evaluation on the clinical efficacy and safety of Tangning Tongluo Capsule in the&#xD;
      treatment of type II diabetes, and provides basis for determining optimal dosage of Tangning&#xD;
      Tongluo capsule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decline glycosylated hemoglobin A1C and blood glucose level</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Decline in Hemoglobin A1C and blood glucose level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The clinical composite safety evaluation of Tangning Tongluo Capsule in the treatment of type II diabetes participants</measure>
    <time_frame>2 months</time_frame>
    <description>Routine check for blood, urine, stool + occult blood, liver function (ALT, AST, AKP, GGT, TBIL), renal function (BuN, Cr), ECG before treatment with 1 times per week.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Accidental Exposure While Preparing Drug for Administration</condition>
  <arm_group>
    <arm_group_label>TNTL capsule and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-4 capsules 3 times a day Used before meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNTL capsule</intervention_name>
    <description>Patients were asked to taken drugs 3 times a day, with each time 3 grains</description>
    <arm_group_label>TNTL capsule and Placebo</arm_group_label>
    <other_name>Tang Ning Tongluo Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients were asked to taken drugs 3 times a day, with each time 3 grains</description>
    <arm_group_label>TNTL capsule and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fulfilled diagnostic criteria for type II diabetes and TCM syndrome diagnostic&#xD;
             criteria.&#xD;
&#xD;
          2. Age between 18-70 years.&#xD;
&#xD;
          3. The blood sugar meet the following criteria: fasting blood glucose ≥ 7.0mmol/L, ≤ 13&#xD;
             mmol/L and (or) ≥ 2 hour postprandial blood glucose 11.1 mmol/L, ≤ 16 mmol/L; eligible&#xD;
             conditions in blood glucose, glycosylated hemoglobin to ≤ 10%.&#xD;
&#xD;
          4. Traditional Chinese medicine symptom score ≥ 4 points.&#xD;
&#xD;
          5. Participated in the experiment voluntarily, and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Durring the cleaning period, blood sugar dropped to below detection diagnosis value&#xD;
             through diet, increasing activity.&#xD;
&#xD;
          2. Secondary diabetes mellitus or nearly a month using insulin; or is the use of insulin&#xD;
             sensitizers (thiazolidine two ketones), repaglinide, Bernard Glenn Nai, alpha&#xD;
             glucoside enzyme inhibitor (acarbose, voglibose), other traditional Chinese medicine.&#xD;
&#xD;
          3. Within the past 1 months, with diabetic ketoacidosis and other acute metabolic&#xD;
             disorders.&#xD;
&#xD;
          4. ALT is 2 times higher than the upper limit of the normal value, Cr is higher than the&#xD;
             upper limit of normal persons.&#xD;
&#xD;
          5. Has severe heart, liver, renal, hematopoietic system disease, or other serious&#xD;
             diseases and mental disease patients.&#xD;
&#xD;
          6. Pregnant, lactating women and prepare for pregnancy.&#xD;
&#xD;
          7. The allergic constitution and the drug allergy known composition.&#xD;
&#xD;
          8. For nearly a month with severe infection or other emergency state, such as trauma,&#xD;
             operation etc..&#xD;
&#xD;
          9. within the past 3 months, participated in the other drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XY Xin, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>ICMJE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianyuan Hospital of Guiyang City</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

